TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
Two Astrazeneca breast cancer projects record apparent pivotal successes in settings where Roche had failed.
The group buys out its partner Genetx, but inconsistent data spook investors.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
A couple of small M&A deals this week shows more developers capitulating to the new reality.
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?